Search

Your search keyword '"Herrera, Concepcion"' showing total 29 results
Start Over Author "Herrera, Concepcion"
29 results on '"Herrera, Concepcion"'

3. Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party

Author

Bazarbachi, Ali, Labopin, Myriam, Angelucci, Emanuele, Gülbas, Zafer, Ozdogu, Hakan, Arat, Mutlu, de Rosa, Luca, Pastano, Rocco, Pioltelli, Pietro, Montserrat, Rovira, Martino, Massimo, Ciceri, Fabio, Koç, Yener, Socié, Gerard, Blaise, Didier, Herrera, Concepcion, Chalandon, Yves, Bernasconi, Paolo, Marotta, Giuseppe, Castagna, Luca, McDonald, Andrew, Visani, Guiseppe, Carluccio, Paola, Vitek, Antonin, Simand, Célestine, Afanasyev, Boris, Rösler, Wolf, Diez-Martin, J.L., Nagler, Arnon, Brissot, Eolia, Giebel, Sebastian, and Mohty, Mohamad

Published
2020
Full Text
View/download PDF

4. Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant

Author

Bento, Leyre, Bastida, José María, García-Cadenas, Irene, García-Torres, Estefania, Rivera, Daniel, Bosch-Vilaseca, Anna, De Miguel, Carlos, Martínez-Muñoz, María Esther, Fernández-Avilés, Francesc, Roldán, Elisa, Chinea, Anabelle, Yáñez, Lucrecia, Zudaire, Teresa, Vaz, Carlos Pinho, Espigado, Ildefonso, López, Javier, Valcárcel, David, Duarte, Rafael, Cabrera, Rafael, Herrera, Concepción, González-Porras, José Ramón, Gutiérrez, Antonio, Solano, Carlos, and Sampol, Antonia

Published
2019
Full Text
View/download PDF

6. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia

Author

Avendano-Sola, Cristina, Ramos-Martinez, Antonio, Munez-Rubio, Elena, Ruiz- Antoran, Belen, de Molina, Rosa Malo, Torres, Ferran, Fernandez-Cruz, Ana, Calderon-Parra, Jorge, Payares-Herrera, Concepcion, de Santiago, Alberto Diaz, Romera-Martinez, Irene, Pintos, Ilduara, Lora-Tamayo, Jaime, Mancheno-Losa, Mikel, Paciello, Maria L., Martinez-Gonzalez, A.L., Vidan-Estevez, Julia, Nunez-Orantos, Maria J., Saez-Serrano, Maria Isabel, Porras-Leal, Maria L., Jarilla-Fernandez, Maria C., Villares, Paula, de Oteyza, Jaime Perez, Ramos-Garrido, Ascension, Blanco, Lydia, Madrigal-Sanchez, Maria E., Rubio-Batlles, Martin, Velasco-Iglesias, Ana, Pano-Pardo, Jose R., Moreno-Chulilla, J.A., Muniz-Diaz, Eduardo, Casas-Flecha, Inmaculada, Perez-Olmeda, Mayte, Garcia-Perez, Javier, Alcami, Jose, Bueno, Jose L., and Duarte, Rafael F.

Subjects
Bacterial pneumonia -- Care and treatment, Pneumonia -- Care and treatment, Hospital patients -- Care and treatment, Health care industry
Abstract

BACKGROUND. Passive immunotherapy with convalescent plasma (CP) is a potential treatment for COVID-19. Evidence from controlled clinical trials is inconclusive. METHODS. We conducted a randomized, open-label, controlled clinical trial at 27 hospitals in Spain. Patients had to be admitted for COVID-19 pneumonia within 7 days from symptom onset and not on mechanical ventilation or high-flow oxygen devices. Patients were randomized 1:1 to treatment with CP in addition to standard of care (SOC) or to the control arm receiving only SOC. The primary endpoint was the proportion of patients in categories 5 (noninvasive ventilation or high-flow oxygen), 6 (invasive mechanical ventilation or extracorporeal membrane oxygenation [ECMO]), or 7 (death) at 14 days. Primary analysis was performed in the intention-to-treat population. RESULTS. Between April 4, 2020, and February 5, 2021, 350 patients were randomly assigned to either CP (n = 179) or SOC (n = 171). At 14 days, proportion of patients in categories 5, 6, or 7 was 11.7% in the CP group versus 16.4% in the control group (P = 0.205). The difference was greater at 28 days, with 8.4% of patients in categories 5-7 in the CP group versus 17.0% in the control group (P = 0.021). The difference in overall survival did not reach statistical significance (HR 0.46, 95% CI 0.19-1.14, log-rank P = 0.087). CONCLUSION. CP showed a significant benefit in preventing progression to noninvasive ventilation or high-flow oxygen, invasive mechanical ventilation or ECMO, or death at 28 days. The effect on the predefined primary endpoint at 14 days and the effect on overall survival were not statistically significant. TRIAL REGISTRATION. Clinicaltrials.gov, NCT04345523. FUNDING. Government of Spain, Instituto de Salud Carlos III., Introduction The pressing need for treatments for the COVID-19 pandemic obliged the medical community and authorities to embrace the use of convalescent plasma (CP) as a potentially effective and easily [...]

Published
2021
Full Text
View/download PDF

8. Outcomes of Unmanipulated Haploidentical Transplantation Using Post-Transplant Cyclophosphamide (PT-Cy) in Pediatric Patients With Acute Lymphoblastic Leukemia

Author

Ruggeri, Annalisa, Galimard, Jacques-Emmanuel, Paina, Olesya, Fagioli, Franca, Tbakhi, Abdelghani, Yesilipek, Akif, Navarro, José Maria Fernandez, Faraci, Maura, Hamladji, Rose-Marie, Skorobogatova, Elena, Al-Seraihy, Amal, Sundin, Mikael, Herrera, Concepcion, Rifón, Jose, Dalissier, Arnaud, Locatelli, Franco, Rocha, Vanderson, and Corbacioglu, Selim

Published
2021
Full Text
View/download PDF

11. Functional Improvement in Patients With Dilated Cardiomyopathy After the Intracoronary Infusion of Autologous Bone Marrow Mononuclear Cells

Author

Suárez de Lezo, José, Herrera, Concepción, Romero, Miguel, Pan, Manuel, Suárez de Lezo, Javier, Jr, Carmona, María Dolores, Jiménez, Rosario, Segura, José, Nogueras, Sonia, Mesa, Dolores, Pavlovic, Djordje, Ojeda, Soledad, Mazuelos, Francisco, Delgado, Mónica, Ruiz, Martin, Castilla, María Luisa, and Torres, Antonio

Published
2013
Full Text
View/download PDF

18. EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma

Author

Michaleas, Sotirios, primary, Penninga, Elisabeth, additional, Hovgaard, Doris, additional, Dalseg, Anne-Marie, additional, Rosso, Aldana, additional, Sarac, Sinan B., additional, Jimenez, Jorge Camarero, additional, Fernández, Lucia López-Anglada, additional, Fernández, Carolina Prieto, additional, Mangas-SanJuan, Victor, additional, Garcia, Isabel, additional, Payares-Herrera, Concepcion, additional, Sancho-López, Aranzazu, additional, Enzmann, Harald, additional, de Castro Lopes Silva, Marcia Sofia Sanches, additional, Duarte, Sílvia, additional, and Pignatti, Francesco, additional

Published
2020
Full Text
View/download PDF

21. Ca‐based bifunctional acid‐basic model‐catalysts for n‐butanol production from ethanol condensation.

Author

Pinzón, Marina, Cortés‐Reyes, Marina, Herrera, Concepcion, Larrubia, Maria Á., and Alemany, Luis J.

Subjects
CHEMICAL engineering, NEAR infrared reflectance spectroscopy, BUTANOL, CONDENSATION, ALDOL condensation, CATALYST supports
Abstract

Ethanol to n‐butanol conversion is a process that can increase the carbon number of alcohols by coupling. There is increasing interest in the mechanisms for n‐butanol production in a simple step through the effective use of bifunctional acid–base catalysts. In this context, commercial hydroxyapatite (HAP) and two synthetized model supported catalysts, Ca/Al2O3 and Ca‐P/Al2O3, were used in bioethanol condensation. Characterization and acid–base sites were considered, and Fourier‐transform infrared (FTIR) spectroscopy and diffuse reflectance infrared Fourier‐transform spectroscopy–mass spectrometry (DRIFT‐MS) reactivity tests were performed in situ, as a first approximation to design a sustainable catalytic process rationally, and with the aim of understanding the process at the catalytic surface. The results indicated that the reactions occur at a large range of temperatures (200–450 °C). Hydroxyapatite and Ca/Al2O3 have similar basic sites (low and medium) and Ca‐P/Al2O3 presented the strongest Brönsted and Lewis combined acid sites. Three major reactions were identified: non‐oxidative dehydrogenation, aldol condensation, and intermolecular reduction, associated with the basic‐acid sites Ca‐O‐Ca/Ca‐O‐P/Ca‐O‐Al. Side reactions also occur involving different acid sites related to Lewis alumina centers favoring ethylene or diethyl‐ether production. © 2020 Society of Industrial Chemistry and John Wiley & Sons Ltd [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

25. Detection of Circulating Antigen-Specific CD8+ Lymphocytes against Leukemia Associated Antigens WT1, PR1 and Survivin Using HLA 0201 Pentamers After Allogeneic Stem Cell Transplantation.

Author

Serrano-Lopez, Juana, primary, Garcia, Joaquin Sanchez, additional, Serrano, Josefina, additional, Martin, Carmen, additional, Rojas, Rafael, additional, Martinez, Francisco, additional, Gomez, Pedro, additional, Rodriguez, Antonia, additional, Garcia-Castellano, Jose Manuel, additional, Casaño, Javier, additional, Herrera, Concepcion, additional, and Gomez, Antonio P. Torres, additional

Published
2009
Full Text
View/download PDF

26. Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210BCR-ABL and p190BCR-ABL after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190BCR-ABL detection precede cytogenetic relapse

Author

Serrano, Josefina, primary, Roman, Jose, additional, Sanchez, Joaquin, additional, Jimenez, Antonio, additional, Castillejo, Juan A., additional, Herrera, Concepcion, additional, Gonzalez, Maria Gracia, additional, Reina, Luisa, additional, Rodriguez, Maria del Carmen, additional, Alvarez, Miguel A., additional, Maldonado, Juan, additional, and Torres, Antonio, additional

Published
2000
Full Text
View/download PDF

27. Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210BCR-ABLand p190BCR-ABLafter allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190BCR-ABLdetection precede cytogenetic relapse

Author

Serrano, Josefina, Roman, Jose, Sanchez, Joaquin, Jimenez, Antonio, Castillejo, Juan A., Herrera, Concepcion, Gonzalez, Maria Gracia, Reina, Luisa, Rodriguez, Maria del Carmen, Alvarez, Miguel A., Maldonado, Juan, and Torres, Antonio

Abstract

We studied lineage-specific chimerism and minimal residual disease (MRD) in sequential posttransplant samples from 55 patients who underwent unmanipulated (n = 44) or partially T-cell–depleted (n = 11) allogeneic bone marrow transplantation (BMT) for chronic myeloid leukemia (CML). Chimerism was assessed by polymerase chain reaction (VNTR [variable number of tandem repeats]-PCR) analysis in highly purified CD19+, CD3+, CD15+, and CD56+ cell fractions, whereas MRD was investigated in whole blood by reverse transcriptase–PCR (RT-PCR) of both p210BCR-ABLand p190BCR-ABLhybrid transcripts. Of 55 patients, 14 (including 6 T-cell–depleted patients) had cytogenetic relapse at 5-80 months and progressed to hematologic relapse, while 41 patients remained in prolonged cytogenetic remission 12-107 months post-BMT. Before leukemia recurrence, patients in the relapse group showed a consistent evolution pattern sequentially featured by persistent p210BCR-ABLpositivity, increasing mixed chimerism (MC) in myeloid cells, p190BCR-ABLpositivity, and, finally, cytogenetic relapse. Myeloid MC preceded cytogenetic relapse by 2-12 months, whereas p190BCR/ABLwas detected 1-6 months prior to cytogenetic relapse in 11 patients and concomitant with cytogenetic relapse in 3 patients. In the remission group, all patients invariably tested negative for p190BCR-ABL; 10 patients tested positive for p210BCR-ABLat variable time-points but showed persistent full donor chimerism (DC), whereas 31 patients tested p210BCR-ABLnegative and displayed full DC or transient MC due to the persistence of recipient T cells. Two patients in the relapse group were successfully reinduced into molecular remission with donor lymphocyte infusion. Sequential molecular analysis after such treatment showed the inverse pattern to that observed prior to relapse, ie, progressive disappearance of p190BCR-ABLtranscripts, conversion of myeloid chimerism to donor type, and, finally, p210BCR-ABLnegativity. We conclude that lineage-specific chimerism and p190BCR-ABLmessenger RNA (mRNA) analyses contribute a better characterization of CML evolution after BMT and enable early identification of patients at the highest risk of relapse.

Published
2000
Full Text
View/download PDF

29. Cell cycle kinetic changes induced by interleukin-3 and interleukin-6 during ex vivo expansion of mobilized peripheral blood CD34 cells.

Author

Sanchez-Garcia J, Torres A, Herrera C, and Alvarez MA

Subjects
Antigens, CD34, Blood Cells, Cell Culture Techniques, Hematopoietic Stem Cell Mobilization, Humans, Interleukin-3 pharmacology, Interleukin-6 pharmacology, Kinetics, Cell Cycle drug effects, Cell Proliferation drug effects, Hematopoietic Stem Cells cytology
Abstract

The long-term repopulating capacity of mobilized peripheral blood (MPB) CD34+ cells can be abrogated during ex vivo expansion due to cell-cycle related changes. In this study, we traced cell cycle kinetic and quiescent status of CD34+ cells during ex vivo expansion with exogenous cytokines. The addition of interleukin-3 (IL-3) and interleukin-6 (IL-6) to early acting cytokines resulted in a significantly lower percentage of cells remaining undivided or in quiescent G0 phase when compared to the use of early acting cytokines alone. We conclude that ex vivo expansion of MPB CD34+ cells with a cocktail of five cytokines yields a highly cycling offspring, which could impair long-term repopulating capacity.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results